Press Releases
Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies
Palleon Presents Preclinical Data on Lead Program E-602 and Novel Bifunctional PD-L1-Targeted Sialidase
Palleon Pharmaceuticals to Present Preclinical Data on Lead Program E-602 and Novel Bifunctional PD-L1-Targeted Sialidase at AACR Annual Meeting
Palleon Pharmaceuticals Announces First Patient Dosed in Phase 1/2 Study of Lead Glyco-Immunology Drug Candidate for Oncology
In the News
With details on lead sialoglycan degrader in place, Palleon raises $100M series B
BioCentury
Palleon battalion bags $100M series B for glycan push
BioWorld
Palleon Pharmaceuticals secures $100m in Series B funding
Pharmaceutical Technology
Jim Broderick reels in a $100M Series B to explore a ‘new and big’ angle of immune regulation
Endpoints
Social Media
Today we're happy to welcome Chris Cole to Palleon! Chris joins us from the @theNCI as our newest Medical Director.… http://8HujHE3O9K
In 2022, @AmericanCancer Society estimates that there will be 1.9 million new cases of cancer in the U.S. and 600,0… http://wCNbi32hgC